Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Lenalidomide + Dexamethasone in RRMM
NCT02030483Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Primary endpoint: Maximum Tolerated Dose at 3 years. Started Feb 2014; status: terminated.
02
Drugs
palbociclib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02030483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030483.